PO.CL04.02 · 临床研究
接受化疗的少数族裔癌症患者的运动偏好与障碍
Exercise preferences and barriers in minority cancer patients undergoing chemotherapy
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:在接受化疗的黑人和拉丁裔癌症患者中,体力活动不足和共病负担的比例过高,然而尽管运动的益处已为人所知,这些群体参与运动肿瘤学试验的比例仍然很低。“测试居家运动策略以改善接受化疗的服务不足少数族裔癌症患者的运动参与度和心血管健康”(THRIVE)试验旨在检验在化疗期间对这些代表性不足群体开展有监督和无监督居家运动的可行性和可接受性。本分析描述了在随机化之前通过结构化问卷收集到的运动偏好。
方法:入组THRIVE试验的参与者完成了基线问卷,评估其运动兴趣、偏好的运动方式、时间安排、感知益处和预期障碍。符合条件的患者为久坐不动、自我认同为黑人或西班牙裔/拉丁裔、并被诊断为乳腺癌、结直肠癌或前列腺癌的患者。采用描述性统计来总结患者特征和调查应答。益处预期问卷采用7分李克特量表评分,范围从−3(非常有害)到+3(非常有益)。运动障碍问卷采用7分李克特量表评分,范围从1(完全没有)到7(非常大)。数据以均值 ± 标准差报告。
结果:截至目前,共有19名黑人或拉丁裔参与者入组本研究,13名参与者返回了问卷(平均年龄55 ± 12岁),包括12名女性乳腺癌患者和1名男性前列腺癌患者。大多数参与者表示有兴趣参加运动项目(84.6%),并感到自己有能力做到(76.9%)。步行(69.2%)和力量训练(53.8%)是最受偏好的方式。最常见的是每周三次(69.2%)、每次30-60分钟(84.6%)的轻度或中度强度运动(38.5%)。令人惊讶的是,最受偏好的开始运动项目的时间是在癌症治疗期间(61.5%),其次是在癌症治疗之前(30.8%)。参与者对所提议的项目报告了很高的预期益处,91.7%将其对总体生活质量(M = 2.9 ± 0.3)和身体功能(M = 2.8 ± 0.9)的影响评为“非常有益”。最常被提及的障碍是感到不适/身体不舒服(M = 4.3 ± 2.1)和感到疲倦或乏力(M = 4.1 ± 2.0),其次是费用(M = 3.8 ± 2.5)和前往健身中心的交通(M = 3.8 ± 2.1)。
结论:黑人和拉丁裔癌症患者对在癌症治疗期间开展有监督的居家运动项目表现出强烈的兴趣和信心。定制运动日程安排并应对不适和乏力等症状可能会提高参与度。解决费用和交通等障碍可能进一步支持依从性。
查看英文原文 English abstract
Background: Physical inactivity and comorbid disease burden are disproportionately high among Black and Latinx cancer patients receiving chemotherapy, yet participation in exercise oncology trials remains low in these groups, despite known benefits. The T esting H ome-based Exe R cise Strategies to I mprove Exercise Participation and Cardio V ascular Health in Unders E rved Minority Patients with Cancer Undergoing Chemotherapy (THRIVE) trial tests the feasibility and acceptability of supervised and unsupervised home-based exercise during chemotherapy in these underrepresented groups. This analysis describes exercise preferences collected through a structured questionnaire administered prior to randomization.
Methods: Participants enrolled in the THRIVE trial completed baseline questionnaires assessing exercise interest, preferred modalities, timing, perceived benefits, and anticipated barriers. Eligible patients were sedentary, self-identified as Black or Hispanic/Latinx, and diagnosed with breast, colorectal, or prostate cancer. Descriptive statistics were used to summarize patient characteristics and survey responses. The Benefit Anticipation Questionnaire was scored using a 7-point Likert scale ranging from −3 (very much harmful) to +3 (very much beneficial). The Exercise Barrier Questionnaire was scored using a 7-point Likert scale, ranging from 1 (not at all) to 7 (very much). Data are reported as mean ± standard deviation.
Results: Nineteen Black or Latinx participants enrolled in the study to date, and 13 participants returned the questionnaire (mean age 55 ± 12 years), including 12 female breast cancer patients and 1 male prostate cancer patient. Most participants expressed interest in participating in an exercise program (84.6%) and felt capable of doing so (76.9%). Walking (69.2%) and strength training (53.8%) were the most preferred modes. Light- or Moderate-intensity exercise (38.5%) performed 30-60 minutes per session (84.6%) three times per week (69.2%) was most common. Surprisingly, the most preferred time to start an exercise program was during cancer treatment (61.5%), followed by before cancer treatment (30.8%). Participants reported high anticipated benefits for the proposed program, with 91.7% rating the impact as “very much beneficial” for both overall quality of life (M = 2.9 ± 0.3) and physical functioning (M = 2.8 ± 0.9). The most frequently cited barriers were feeling sick/not feeling well (M = 4.3 ± 2.1) and feeling tired or fatigued (M = 4.1 ± 2.0), followed by cost (M = 3.8 ± 2.5) and traveling to the fitness center (M = 3.8 ± 2.1).
Conclusion: Black and Latinx cancer patients expressed strong interest and confidence in home-based, supervised exercise programs during cancer treatment. Tailoring exercise schedules and addressing symptoms such as sickness and fatigue may enhance participation. Addressing barriers such as cost and travel may further support adherence.
利益披露 Disclosure
H. Yan, None..
S. Amini, None..
J. D. Cannon, None..
A. Pecha, None..
R. L. Wilson, None..
C. N. Christopher, None..
M. K. Norris, None..
C. M. Dieli-Conwright, None.